Aging Androgens/metabolism Anti-Inflammatory Agents Humans Inflammation Male *Prostatic Hyperplasia benign prostatic hyperplasia disease progression pathogenesis commercial or financial relationships that could be construed as a potential conflict of interest.

Disease Progression Humans Lower Urinary Tract Symptoms/etiology Male Prostatic Hyperplasia/complications/*drug therapy Risk Factors Time Factors Treatment Outcome Benign prostatic hyperplasia Early treatment Luts Outcomes complications Pharmacological treatment Prostate Surgery

Disease Progression Humans Kallikreins/blood Male Metabolic Syndrome Organ Size Prostate/growth & development/pathology/physiopathology Prostate-Specific Antigen/blood Prostatic Hyperplasia/pathology/physiopathology

Humans Smoking/adverse effects/epidemiology *Non-Muscle Invasive Bladder Neoplasms *Urinary Bladder Neoplasms/epidemiology/etiology *Carcinoma Transitional Cell Prognosis Neoplasm Recurrence Local/epidemiology Current smoker Non-muscle-invasive bladder cancer Progression Recurrence Smoking

Humans Immunotherapy Inflammation Prognosis Progression-Free Survival *Urinary Bladder Neoplasms

#BladderCancer #blcsm #uroonc cystoscopy gross appearance multiplicity non-muscle-invasive bladder cancer progression recurrence size

Adult Aged Aged 80 and over Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use B7-H1 Antigen/antagonists & inhibitors Carcinoma/*drug therapy/immunology/mortality/pathology Clinical Decision-Making Female Humans Immune Checkpoint Inhibitors/adverse effects/*therapeutic use Male Middle Aged Patient Selection Progression-Free Survival Time Factors Urinary Bladder Neoplasms/*drug therapy/immunology/mortality/pathology Urothelium/*drug effects/immunology/pathology Immune-checkpoint inhibitor Meta-analysis Programmed death-ligand 1 Urothelial carcinoma interests/personal relationships which may be considered as potential competing interests: The authors certify that all conflicts of interest including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the article are listed as follows: Shahrokh Shariat owns or co-owns the following patents: methods to determine prognosis after therapy for prostate cancer. Granted 2002-09-06. Methods to determine prognosis after therapy for bladder cancer. Granted 2003-06-19. Prognostic methods for patients with prostatic disease. Granted 2004-08-05. Soluble Fas: urinary marker for the detection of bladder transitional cell carcinoma. Granted 2010-07-20. He has a consulting or advisory role for the following: Astellas Astra Zeneca Bayer BMS Cepheid Ferring Ipsen Jansen Lilly MSD Olympus Pfizer Pierre Fabre Roche Sanochemia Sanofi Takeda Urogen and Wolff. All remaining authors have declared no conflicts of interest.

Administration Intravesical Antineoplastic Agents/*administration & dosage/adverse effects Clinical Trials as Topic Disease Progression Humans Neoplasm Metastasis *Neoplasm Recurrence Local Network Meta-Analysis Progression-Free Survival Risk Assessment Risk Factors Time Factors Urinary Bladder Neoplasms/*drug therapy/mortality/pathology

Carcinoma Transitional Cell/*classification/*genetics/mortality Humans Predictive Value of Tests Survival Rate Treatment Outcome Urinary Bladder Neoplasms/*classification/*genetics/mortality Bladder cancer Molecular classification Molecular subtype Prognosis Progression Urothelial carcinoma

Animals Diabetes Mellitus/*physiopathology Disease Progression Humans Obesity/*complications Urinary Bladder Neoplasms/etiology/*pathology all-cause mortality cancer specific mortality diabetes disease recurrence obesity overweight urinary bladder cancer commercial or financial relationships that could be construed as a potential conflict of interest.

Carcinoma Transitional Cell/*drug therapy Humans Prognosis Receptors Fibroblast Growth Factor/*antagonists & inhibitors Urinary Bladder Neoplasms/*drug therapy Bladder cancer Fgfr FGFR inhibitors Fgfr3 Progression Urothelial carcinoma

Adjuvants Immunologic/administration & dosage Administration Intravesical Antibiotics Antineoplastic/administration & dosage/adverse effects Antimetabolites Antineoplastic/*administration & dosage/adverse effects BCG Vaccine/administration & dosage Bias Cause of Death Confidence Intervals Deoxycytidine/administration & dosage/adverse effects/*analogs & derivatives Disease Progression Drug Administration Schedule Humans Mitomycin/administration & dosage/adverse effects Neoplasm Recurrence Local/*drug therapy/mortality/prevention & control Randomized Controlled Trials as Topic Saline Solution/administration & dosage Urinary Bladder Neoplasms/*drug therapy/mortality/pathology/prevention & control Gemcitabine

Adult Aged Aged 80 and over B7-H1 Antigen/genetics/*immunology Female Humans Immune Checkpoint Inhibitors/*administration & dosage *Immunotherapy Male Middle Aged Programmed Cell Death 1 Receptor/genetics/*immunology Progression-Free Survival Randomized Controlled Trials as Topic Treatment Outcome Urinary Bladder Neoplasms/genetics/immunology/mortality/*therapy efficacy immunotherapy meta-analysis safety urothelial cancer this study.

Disease Progression Humans Muscle Smooth/pathology Neoplasm Grading Neoplasm Invasiveness Neoplasm Staging Treatment Failure Urinary Bladder/pathology Urinary Bladder Neoplasms/*pathology/*therapy *Watchful Waiting Active surveillance Non-Muscle Invasive bladder cancer Urothelial neoplasm

Carcinoma Transitional Cell/epidemiology/*pathology Disease Progression Humans Neoplasm Invasiveness Neoplasm Recurrence Local/epidemiology Neoplasm Staging Prognosis Urinary Bladder Neoplasms/epidemiology/*pathology Bladder cancer Progression Staging Substage T1 Urothelial carcinoma pT1

Biomarkers/urine DNA Mutational Analysis DNA Neoplasm/*urine Disease Progression Humans Mutation Neoplasm Recurrence Local/*diagnosis/genetics/*urine Sensitivity and Specificity Urinary Bladder Neoplasms/*diagnosis/genetics/*urine #BladderCancer #blcsm biomarkers molecular diagnostics urinary bladder neoplasms urine analysis Amsterdam UMC location VUmc. J. Bosschieter R.D.M. Steenbergen and J.A. Nieuwenhuijzen are inventors on patent(s) related to the work.

Carcinoma Transitional Cell/diagnosis/epidemiology/*therapy Child Combined Modality Therapy *Disease Management Disease Progression Global Health Humans Incidence Risk Factors Survival Rate/trends Urinary Bladder/*pathology Urinary Bladder Neoplasms/diagnosis/epidemiology/*therapy Management Pediatric Surveillance Transurethral resection Urothelial cell carcinoma

Carcinoma Papillary/mortality/pathology/*therapy Disease Progression Humans Neoplasm Staging Progression-Free Survival Risk Assessment Risk Factors Time Factors Urinary Bladder Neoplasms/mortality/pathology/*therapy Urothelium/*pathology Bacillus Calmette-Guérin therapy Bladder cancer Bladder sparing Immediate cystectomy Micropapillary Prognosis Transurethral resection Urothelial carcinoma Variant histology

*DNA Methylation DNA Neoplasm/*metabolism Humans Prognosis Urinary Bladder Neoplasms/*diagnosis/*genetics Biomarker Bladder cancer DNA methylation Overall survival Progression-free survival

*DNA Methylation Disease Progression Female Genes APC/*physiology Humans Male *Promoter Regions Genetic *Urinary Bladder Neoplasms/genetics/pathology/urine